How Low Can Gilenia Go? Panel Wants Reduced-Dose Phase IV Trial

FDA should approve Novartis' Gilenia (fingolimod), an oral tablet intended to treat relapsing remitting multiple sclerosis, but should require the company to test a lower dose of the medication in a post-market clinical trial due to the product's many risks, a mostly united advisory panel said June 10